ReviewCurrent topics in microbiology and immunology2010
PI3K: from the bench to the clinic and back.
Review in Current topics in microbiology and immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 78 citations in OpenAlex.
- LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models.The Journal of clinical investigation · 2025Article
- Role of PI3 Kinases in Cell Signaling and Soleus Muscle Atrophy During Three Days of Unloading.International journal of molecular sciences · 2025Article
- Genetic ablation of the isoform γ of PI3K decreases antidepressant efficacy of ketamine in male mice.IBRO neuroscience reports · 2024Article
- Anti-Cancer and Anti-Proliferative Potential of Cannabidiol: A Cellular and Molecular Perspective.International journal of molecular sciences · 2024Review
- Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features ofDiagnostics (Basel, Switzerland) · 2023Article
- Live Cells Imaging and Comparative Phosphoproteomics Uncover Proteins from the Mechanobiome inInternational journal of molecular sciences · 2023Article
- Systematic identification of biochemical networks in cancer cells by functional pathway inference analysis.Bioinformatics (Oxford, England) · 2023Article
- Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.Pharmaceutics · 2022Review
- Advances in chemical proteomic evaluation of lipid kinases-DAG kinases as a case study.Current opinion in chemical biology · 2021Review
- Article
- ACTH treatment promotes murine cardiac allograft acceptance.JCI insight · 2021Article
- Toll receptors remodel epithelia by directing planar-polarized Src and PI3K activity.Developmental cell · 2021Article
- Salvianolic acid B suppresses EMT and apoptosis to lessen drug resistance through AKT/mTOR in gastric cancer cells.Cytotechnology · 2021Article
- Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinson's disease patients.Scientific reports · 2021Article
- Evodiamine Inhibits Gastric Cancer Cell ProliferationEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.International journal of hematology · 2020Article
- Role of cancer stem cells in the development of giant cell tumor of bone.Cancer cell international · 2020Review
- PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.International journal of molecular sciences · 2019Review
- Disrupted neuronal trafficking in amyotrophic lateral sclerosis.Acta neuropathologica · 2019Review
- Phosphatidylinositol Kinases and Phosphatases inFrontiers in cellular and infection microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here, we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here.PI3K has become a very intense area of research, with over 2,000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost invariably encounter roadblocks, often exposing unresolved questions in the basic understanding of the target. PI3K will most likely be no exception. Below, we describe some of these early "surprises" and how these inform and shape basic science investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.